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 In the present study, acute hypoxia was induced in 19 pa-
tients with chronic respiratory disease to evaluate the corre 
lation between pulmonary circulation kinetics and adrenomedullin 
(AM) levels. Using radioimmunoassay (RIA), pulmonary cir-
culation kinetics were evaluated before and after hypoxic 
loading (13% oxygen for 15 minutes) by determining AM 
levels in plasma obtained from the pulmonary artery (PA) 
and the right femoral artery (FA). There were no signifi-
cant differences in pre-hypoxia plasma AM levels between 
samples obtained from the PA and FA, and plasma AM lev-
els did not change after hypoxic loading. Subjects were classi-
fied into two groups [responders (R) and non-responders 
(NR) ] to evaluate changes in the mean pulmonary arterial
pressure(△MPAP).　 There　 were　 no　 changes　 in　 AM　 levels　 be-
tween these two groups in either the PA or FA after hypoxic 
loading. These results suggest that AM do not appear to be 
related to hypoxic pulmonary vascular response to acute 
hypoxic loading in patients with chronic respiratory disease.
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to be clarified. 
 Adrenomedullin (AM) is a newly-identified vasodilative 
peptide isolated from human pheochromocytoma tissues." 
Markedly potent human AM mRNA expression has 
been observed in pheochromocytoma tissue and the 
adrenal medulla as well as in the lungs'. Specific recep-
tors for AM have been reported in cultured rat vascu-
lar endothelial cells (EC) as well as in vascular smooth 
muscle cells (VSMC)." The vasodilative action of AM 
is considered to result from nitric oxide (NO) produc-
tion in EC and increased cAMP levels in VSMC.8' The 
level of AM receptors is reportedly high in the rat 
lung." Moreover, plasma AM levels are significantly 
low in the right heart circulatory system compare to 
that in the left."' Thus, the pulmonary circulation may 
intrinsically involve in plasma AM clearance. 
 To evaluate the pathophysiological significance of AM, 
hypoxia was induced in patients with chronic respira-
tory disease, and pulmonary circulation kinetics were 




 In 1946, Von Euler and Liljestrand first reported 
that pulmonary vascular constriction was induced by a 
rapid decrease in alveolar oxygen levels, resulting in in-
creased pulmonary arterial pressure." This phenome-
non was referred to thereafter as hypoxic pulmonary 
vasoconstriction (HPV), and several studies have been 
conducted.'-" However, the mechanism of HPV remains
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Subjects 
 Subjects consisted of 19 patients with chronic respi-
ratory disease (8 men and 11 women). Cases included 
pulmonary emphysema (n=6), diffuse panbronchiolitis 
(n=2), pulmonary tuberculosis sequela (n=2), atypi-
cal mycobacteriosis (n=4), pulmonary fibrosis (n=1), 
pulmonary aspergilloma (n=2) and collagen disease of 
the lung (n=2). Diagnoses were based on physical ex-
aminations, hematological examination, chest roentgen-
ography, computed tomography, pulmonary function 
test, transbronchial lung biopsy and open lung biopsy. 
Examinations were performed in each patient during 
clinically stable phases of the disease course. Table 1
shows patient ages and findings on arterial blood gas 
analysis, while Table 2 shows findings on pulmonary 
function test. Informed consent was obtained from all 
patients.
Table 1. Patient characteristics (n=19).
Age (years) 65 ± 7 
PaCO2 (Torr) 41.1 ± 4.7 
Pa02 (Torr) 86.5 ± 13.9 
Pv02 (Torr) 42.3 ± 8.4 
pH 7.417 ± 0.03
Values are means±SD. PaCO2: arterial carbon dioxide tension, Pa02: ar-
terial oxygen tension, Pv02: pulmonary arterial oxygen tension.
Table 2. Pulmonary function tests of all subjects.
atient No. Diagnosis FEV,/FVC(%) VC(%predicted) DLCO(%predicted) 
   1 PE 54.8 50.6 58.8 
   2 AM 85.2 93.6 72.1 
   3 PE 85.2 58.6 96.8 
  4 PE 59.0 97.0 88.5 
  5 AM 69.5 102.0 84.8 
  6 CL 70.0 45.8 72.6 
  7 AM 86.1 51.5 52.4 
  8 PT 94.2 104.3 109.1 
  9 DPB 64.5 115.8 88.5 
  10 AM 79'3 45.7 122.0 
  11 PE 79.9 124.6 73.0                          60
.4   12 PE 
571 101.7 70.8 
  13 PA 84 .6 84.6 83.5 
  14 PA 84 .8 78.9 67.1 
  15 PT 72 .8 79.8 72.8 
  16 CL 94 .6 57.4 27.0 
  17 PF 82.7 79.4 49.7 
  18 DPB 78.8 67.2 64.7 
  19 PE 25.8 77.1 28.2
PE: pulmonary emphysema, AM: atypical mycobacterosis, CL: collagen 
disease of the lung, PT: pulmonary tuberculosis sequela, DPB: diffuse 
panbronchiolitis, PA: pulmonary aspergilloma, PF: pulmonary fibrosis, 
FEV,/FVC: forced vital capacity expired in is, VC: vital capacity, 
DLCO: carbon monoxide diffusing capacity.
Methods 
 Administration of drugs that influence circulation ki-
netics or the central nervous system was discontinued 
on the day before examination. All examinations were 
performed on fasting patients without premedication. 
Right heart catheterization was performed using a Swan-
Ganz catheter (model TF002H-7F, Baxter Healthcare) via 
the right femoral vein with patients in the supine rest-
ing position to determine pulmonary capillary wedge 
pressure (PCWP), mean pulmonary arterial pressure 
(MPAP ), and mean right atrial pressure (MRAP). Cardiac 
output (CO) was determined by the thermodilution 
method, using REF-1 ejection fraction/CO computer 
(Edwards Critical Care Division). Body surface area 
(BSA) was calculated according to the by DuBois 
formula,"' and cardiac index (CI) was obtained by the
following equation based on the CO and BSA values: 
CI = CO/BSA (1/min/m2) 
 Total pulmonary vascular resistance (TPR) and pul-
monary vascular resistance (PVR) were calculated ac-
cording to the following equations: TPR = MPAP/CO 
X80 (dyne'sec'cm-5). PVR = (MPAP - PCWP) /COX 80 
(dyne'sec'cm-5). 
 A 20G catheter (Arterial Line Kit, USA) was in-
serted via the right femoral artery (FA) to determine 
the mean arterial pressure (MAP) as well as to collect 
blood samples. Blood samples were also collected from 
the pulmonary artery (PA) for AM level determina-
tion and blood gas analysis. Blood gases were analyzed 
using a Ciba-Corning pH/blood gas analyzer fitted with 
a cooximeter. Subjects were instructed to inhale mixed 
gas consisting of 13% oxygen and nitrogen, which was 
filled in a Douglas bag, via a face mask connected to 
the Douglas bag with a one-way valve. Pulmonary func-
tion test was performed using an Autospirometer System 
9 (Minato Medical Corporation) within one week after 
the right heart catheterization.
Protocol 
 When subjects were instructed to inhale the room 
air, PCWP, MPAP, MRAP, MAP and CO were deter-
mined. Then, a Swan-Ganz catheter was left in the 
main pulmonary artery (MPA) to collect blood sam-
ples from the PA for AM level determination and for 
blood gas analysis. Blood samples were also collected 
from the FA. Subsequently, patients were instructed to 
inhale a mixed gas containing 13% oxygen and nitro-
gen using a face mask, and MPAP and MAP were de-
termined continuously. Fifteen minutes later, PCWP, 
MPAP, MRAP, MAP and CO were redetermined. Simul-
taneously, blood samples were again collected from the 
PA and FA for AM level determination and for blood 
gas analysis. The face mask was removed from the 
subjects immediately after the final collection. There 
were no early or late side effects observed after right 
heart catheterization or 13% oxygen inhalation in any 
patient.
Measurement of AM 
 Plasma AM concentrations were analyzed before and 
after hypoxia. Blood samples for analysis of AM were 
drawn by ice-chilled syringe, transferred into polypro-
pylene tubes containing EDTA and Aprotinin and 
stored at 0°C. Plasma was separated by centrifugation 
for 15 minutes at 01C and immediately frozen and 
stored at -70'C until radioimmunoassay (RIA). Plasma 
AM concentrations were determined by RIA, as previ-
ously described and compared with mean peripheral 
blood concentrations reported for normotensive sub-
jects (18 ± 2 pg/ml).121
Statistical analysis 
 All data are expressed as mean ± SD. Within-group 
comparisons were made using paired t-tests, and between-
group comparisons were made using unpaired t-tests. 
P < 0.05 was considered significant.
hypoxic loading. 
 Based on changes in MPAP before and after hypoxic 
loading ( AMPAP), subjects were classified into two 
groups [responders (R group, AMPAP z 5mmHg) and 
non-responders (NR group, AMPAP < 5mmHg)]. When 
subjects inhaled room air, TPR and PVR were higher 
in the R group than in the NR group. The magnitude 
of change in TPR (ATPR) was significantly greater in 
the R group compared with the NR group (95.5 ± 58.2 
dyne'sec'cm-5, and 27.5 ± 44.0 dyne'sec'cm-5, respectively; 
P < 0.05). In contrast, the change in CI (ACI) did not
Results
 During room air inhalation, the circulation kinetics 
of all subjects remained within the normal range 
(heart rate, HR: 77.3 ± 11.3 beats/min, PCWP: 5.2 ± 
2.8 mmHg, MPAP: 14.3 ± 4.2 mmHg, MRAP: 2.4 ± 1.9 
mmHg, MAP: 103.8 ± 13.9 mmHg, CI: 3.3 ± 0.8 1/min 
/m2). Plasma AM levels did not differ significantly be-
tween samples taken from the PA and FA (71.9 ± 69.8 
pg/ml, and 61.1 ± 46.5 pg/ml, respectively) (Fig. 1). 
Table 3 shows circulation kinetics, blood gases and 
AM levels determined 15 minutes after hypoxic load-
ing. Arterial oxygen tension (Pa02) and pulmonary ar-
terial oxygen tension (Pv02) were significantly de-
creased under hypoxic loading. The increased HR re-
flected the decreases in Pa02 and Pv02, PCWP, MRAP, 
MAP and CI did not change under hypoxic loading; 
however, MPAP, TPR and PVR were increased signif-
icantly. AM levels in PA and FA did not change after
Table 3. Pre-hypoxic and hypoxic hemodynamic values and 
blood gas and plasma AM levels.
                     Room air 13%02 P value 
HR (beats/min) 77.3 ± 11.3 91.5 ± 12.0 < 0.01 
PCWP (mmHg) 5.2 ± 2.8 5.4 ± 2.8 NS 
MPAP (mmHg) 14.3 ± 4.2 19.7 ± 6.0 < 0.01 
MRAP (mmHg) 2.4 ± 1.9 2.2 ± 2.1 NS 
MAP (mmHg) 103.8 ± 13.9 107.7 ± 18.1 NS 
CI (1/min/m2) 3.3 ± 0.8 3.5 ± 0.5 NS 
TPR (dyne'sec'cm-5) 249.0 ± 84.2 315.9 ± 115.3 < 0.01 
PVR (dyne'sec'cm-5) 156.5 ± 65.2 228.9 ± 97.1 < 0.01 
PaCO2 (Torr) 41.1 ± 4.7 39.2 ± 3.0 < 0.01 
Pa02 (Torr) 86.5 ± 13.9 44.1 ± 6.2 < 0.01 
Pv02 (Torr) 42.3 ± 8.4 31.3 ± 2.9 < 0.01 
AM (PA) (pg/ml) 71.9 ± 69.8 65.3 ± 57.5 NS 
AM (FA) (pg/ml) 61.1 ± 46.5 56.2 ± 34.8 NS
Values are means±SD. HR: heart rate, PCWP: pulmonary capillary 
wedge pressure, MPAP: mean pulmonary arterial pressure, MRAP: mean 
right atrial pressure, MAP: mean arterial pressure, CI: cardiac index, 
TPR: total pulmonary resistance, PVR: pulmonary vascular resistance, 
PaCO2: arterial carbon dioxide tension, PaO2: arterial oxygen tension, 
Pv02: pulmonary arterial oxygen tension, AM: adrenomedullin, PA: the 
pulmonary artery, FA: the right femoral artery, NS: not-significant.
Table 4. Main functional and hemodynamic values in re-
sponders and non-responders.
                      Responders Non-responders P value 
                    (n=11) (n=8) 
Age (years) 66.2 ± 7.7 62.8 ± 7.1 NS 
FEV,/FVC (%) 74.3 ± 14.3 70.6 ± 22.0 NS 
VC (%predicted) 77.5 ± 27.3 83.3 ± 21.9 NS 
DLCO (%predicted) 72.7 ± 25.1 72.8 ± 29.8 NS 
PaCO2 (Torr) 41.6 ± 5.0 40.4 ± 4.5 NS 
Pa02 (Torr) 86.7 ± 13.5 86.3 ± 15.3 NS 
Pv02 (Torr) 40.8 ± 2.5 44.3 ± 12.7 NS 
MPAP (mmHg) 15.4 ± 4.8 12.9 ± 2.6 NS 
CI (1/min/m2) 3.1 ± 0.6 3.5 ± 1.1 NS 
TPR (dyne'sec'cm5) 281.4 ± 86.9 204.6 ± 59.7 < 0.05 
PVR (dyne'sec'cm-5) 189.9 ± 62.1 110.6 ± 35.3 < 0.01
Fig. 1. Comparison of baseline plasma PA and FA AM con-
centrations in 19 patients with chronic respiratory disease. 
AM: adrenomedullin, PA: the pulmonary artery, FA: the right 
femoral artery, NS: not-significant.
Values are means±SD. FEV,/FVC: forced vital capacity expired in ls, 
VC: vital capacity, DLCO: carbon monoxide diffusing capacity, PaCO2: 
arterial carbon dioxide tension, Pa02: arterial oxygen tension, Pv02: pul-
monary arterial oxygen tension, MPAP: mean pulmonary arterial pres-
sure, CI: cardiac index, TPR: total pulmonary resistance, PVR: pulmo-
nary vascular resistance, NS: not-significant.
differ significantly between these two groups (0.28 ± 
0.38 1/min/m2, and 0.15 ± 0.87 1/min/m2, respectively). 
There were no significant differences in age, pulmo-
nary function or blood gases (Table 4). There were no 
significant differences between these two groups in 
plasma AM levels from the PA and FA samples [R 
(PA): 61.9 ± 73.7 pg/ml, and NR (PA): 85.8 ± 66.4 
pg/ml, and R (FA) : 50.6 ± 42.4 pg/ml, and NR (FA) : 
75.5 ± 50.7 pg/ml, respectively) ]. PA and FA plasma 
AM levels did not change significantly after hypoxic 
loading (Fig. 2).
Fig. 2. Changes in AM after acute hypoxia. AM: adrenomedullin, 
PA: the pulmonary artery, FA: the right femoral artery, 
Responders: changes in mean pulmonary arterial pressure be-
fore and after hypoxic loading ( OMPAP) z 5 mmHg, Non-
responders: LMPAP < 5 mmHg, NS: not-significant.
Discussion
 Adrenomedullin (AM), consisting of 52 amino acids, 
has one intramolecular disulfide bond and shows slight 
homology with calcitonin gene-related peptide (CGRP).5' 
The vasodilative action of AM is equivalent to that of 
CGRP, the most potent previously-known vasodilative 
peptide. Plasma AM levels have been reported to in-
crease in heart failure and hypertension, 13,14) and have
been positively correlated with pulmonary arterial pres-
sure (PAP).") Moreover, when pulmonary hypertensive 
rats treated with monocrotaline were compared with 
healthy control rats, AM levels in the right ventricle 
and peripheral blood were observed to be significantly 
higher in the monocrotaline-treated rats than in the 
control rats, and high mRNA expression levels were 
observed in the right ventricle of the treated rats.") 
When human AM was injected into rats via the ca-
rotid artery, PAP did not change."' However, AM de-
creased PAP dose-dependently after pulmonary vascu-
lar contractility had been increased by U-46619, an 
analog of thromboxane A2.17"8' The action of AM in the 
pulmonary circulation was contrary to the increase in 
PAP. 
 It is generally accepted that the rise in PAP during 
acute hypoxia in healthy subjects is due to the com-
bined effect of increased PVR and increased CL19-2" In 
patients with chronic respiratory disease with pulmonary 
hypertension, Saadjian et al.") showed that hypoxic 
breathing further increased MPAP but did not affect 
CI. A significant elevation in MPAP, TPR and PVR but 
not significant elevation in CI was observed during 
hypoxic breathing in ours subjects. ATPR was signifi-
cantly higher in the R group compared with the NR 
group, while ACI was not different between these two 
groups. This finding suggests that the magnitude of 
the rise in PAP during hypoxia depends on pulmonary 
vascular reactivity. 
  It has been reported that pulmonary vascular re-
sponse to acute alveolar hypoxia differs among indi-
viduals and species. The number of VSMC of the PA 
as well as different reactivities of substances that were 
released in response to acute hypoxia can be attributed 
to these differences in pulmonary vascular response .25,26) 
In the present study, pulmonary vascular response to 
acute hypoxia varied, resulting in the classification of 
42% of patients as non-responders. Beard et al. re-
ported 28% of healthy subjects that did not respond 
to hypoxia [fractional concentration of oxygen in in-
spired gas (FiO2) = 12 % ],21) Fishman et al. reported 
50% (Fi02 = 12 - 14%). Furthermore, Weitzenblum et 
al. reported 50% of patients with chronic bronchitis to 
be non-responders to hypoxia (Fi02 = 13% ) .28) 
 In the present study, plasma AM levels were higher 
in patients with chronic respiratory disease than in 
normotensive subjects and there were no significant 
differences between PA and FA AM levels in patients 
with chronic respiratory disease. This differed from re-
sults reported in previous studies. Moreover, AM levels 
in PA and FA did not change after hypoxic loading. 
No significant differences in plasma AM levels were 
observed between the R and NR groups (Fig. 2). These
results suggest that pulmonary vascular response to 
acute hypoxia is not related to AM release. Moreover, 
AM did not appear to decrease the acute hypoxia-
induced pulmonary vascular response in patients with 
chronic respiratory disease. When AMPAP was evalu-
ated after inhalation of air containing 2% oxygen for 
8 minutes in rats, AMPAP was significantly decreased 
in the rats treated with AM in comparison to that in 
rats without the treatment. The decrease in AMPAP 
tended to be AM dose-dependent. In rats exposed to 
hypoxia for 7 days, AMPAP was further markedly de-
creased. In a binding experiment using 125I-AM, al-
though the number of AM receptors in the lung 
showed a greater increase in chronic hypoxic rats than 
in control rats, levels of AM mRNA expression did not 
change .21' These findings indicate that AM might be 
related to acute hypoxia-induced pulmonary vascular 
response in some way. In the present study, we deter-
mined AM levels in PA and FA blood. During acute 
hypoxia, if AM is released into the pulmonary tissue 
or the number of AM receptors increase in the lung, 
such changes may not be reflected by plasma AM lev-
els. Moreover, since hypoxia was induced for only a 
short time (15 minutes), plasma AM levels might not 
have been apparent. 
 When healthy persons without history of cardiopul-
monary disease are subjected rapidly to high-altitudes, 
high-altitude pulmonary edema (HAPE) sometimes oc-
curs. HPV is reported as a major factor in HAPE. Thus, it 
is reported that the pulmonary vascular response to 
acute hypoxia is increased in HAPE patients in com-
parison to that in healthy subjects. Therefore, HAPE 
patients may have a constitutional abnormality in ad-
aptation to high-altitudes."' When acute hypoxia (10% 
oxygen for 15 minutes) was induced in both HAPE 
patients and healthy subjects to determine endothelin-
1 (ET-1) levels in the peripheral blood, no significant 
differences were observed between the two groups ei-
ther before or after hypoxic loading."' In the cultured 
rat VSMC, rat or human AM was shown to inhibit ET-
1 production induced by thrombin and platelet-derived 
growth factors. Moreover, rat or human AM increased 
intracellular cAMP levels, which correlated with the 
inhibition of ET-1 production. However, neither rat nor 
human AM decreased baseline ET-1 production.32' 
Therefore, it is speculated that AM acts in part on ET-
1 production in VSMC in a paracrine manner, thus 
controlling vascular response. Since AM and ET-1 act 
in both paracrine and autocrine manners, such changes 
in AM may not be reflected in plasma AM levels. 
 In summary, AM did not appear to be related to 
acute pulmonary vascular response in patients with 
chronic respiratory disease. However, various issues
remain to be clarified. Therefore, further evaluations 
are necessary.
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